Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Down-Regulation of miRNA-708 Promotes Aberrant Calcium Signaling by Targeting Neuronatin in a Mouse Model of Angelman Syndrome.

Vatsa N, Kumar V, Singh BK, Kumar SS, Sharma A, Jana NR.

Front Mol Neurosci. 2019 Feb 13;12:35. doi: 10.3389/fnmol.2019.00035. eCollection 2019.

2.

Neuronatin-mediated aberrant calcium signaling and endoplasmic reticulum stress underlie neuropathology in Lafora disease.

Sharma J, Mukherjee D, Rao SN, Iyengar S, Shankar SK, Satishchandra P, Jana NR.

J Biol Chem. 2013 Mar 29;288(13):9482-90. doi: 10.1074/jbc.M112.416180. Epub 2013 Feb 13.

3.

Rescue of altered HDAC activity recovers behavioural abnormalities in a mouse model of Angelman syndrome.

Jamal I, Kumar V, Vatsa N, Shekhar S, Singh BK, Sharma A, Jana NR.

Neurobiol Dis. 2017 Sep;105:99-108. doi: 10.1016/j.nbd.2017.05.010. Epub 2017 May 30.

PMID:
28576709
4.

Ube3a loss increases excitability and blunts orientation tuning in the visual cortex of Angelman syndrome model mice.

Wallace ML, van Woerden GM, Elgersma Y, Smith SL, Philpot BD.

J Neurophysiol. 2017 Jul 1;118(1):634-646. doi: 10.1152/jn.00618.2016. Epub 2017 May 3.

5.

Defective glucocorticoid hormone receptor signaling leads to increased stress and anxiety in a mouse model of Angelman syndrome.

Godavarthi SK, Dey P, Maheshwari M, Jana NR.

Hum Mol Genet. 2012 Apr 15;21(8):1824-34. doi: 10.1093/hmg/ddr614. Epub 2012 Jan 3.

PMID:
22215440
6.

Impaired adult hippocampal neurogenesis and its partial reversal by chronic treatment of fluoxetine in a mouse model of Angelman syndrome.

Godavarthi SK, Dey P, Sharma A, Jana NR.

Biochem Biophys Res Commun. 2015 Sep 4;464(4):1196-1201. doi: 10.1016/j.bbrc.2015.07.103. Epub 2015 Jul 29.

PMID:
26231800
7.

Decreased Axon Caliber Underlies Loss of Fiber Tract Integrity, Disproportional Reductions in White Matter Volume, and Microcephaly in Angelman Syndrome Model Mice.

Judson MC, Burette AC, Thaxton CL, Pribisko AL, Shen MD, Rumple AM, Del Cid WA, Paniagua B, Styner M, Weinberg RJ, Philpot BD.

J Neurosci. 2017 Aug 2;37(31):7347-7361. doi: 10.1523/JNEUROSCI.0037-17.2017. Epub 2017 Jun 29.

8.

Environmental Enrichment Improves Behavioral Abnormalities in a Mouse Model of Angelman Syndrome.

Jamal I, Kumar V, Vatsa N, Singh BK, Shekhar S, Sharma A, Jana NR.

Mol Neurobiol. 2017 Sep;54(7):5319-5326. doi: 10.1007/s12035-016-0080-3. Epub 2016 Sep 1.

PMID:
27581300
9.

Neuronal overexpression of Ube3a isoform 2 causes behavioral impairments and neuroanatomical pathology relevant to 15q11.2-q13.3 duplication syndrome.

Copping NA, Christian SGB, Ritter DJ, Islam MS, Buscher N, Zolkowska D, Pride MC, Berg EL, LaSalle JM, Ellegood J, Lerch JP, Reiter LT, Silverman JL, Dindot SV.

Hum Mol Genet. 2017 Oct 15;26(20):3995-4010. doi: 10.1093/hmg/ddx289.

10.
11.

Imprinting effects of UBE3A loss on synaptic gene networks and Wnt signaling pathways.

Lopez SJ, Laufer BI, Beitnere U, Berg EL, Silverman JL, O'Geen H, Segal DJ, LaSalle JM.

Hum Mol Genet. 2019 Nov 15;28(22):3842-3852. doi: 10.1093/hmg/ddz221.

PMID:
31625566
12.

[From pathogenesis to treatment of genetic intellectual disabilities: a lesson from Angelman syndrome research].

Saitoh S.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2013 Jun;33(3):127-30. Review. Japanese.

PMID:
25069246
13.

Reversal of reduced parvalbumin neurons in hippocampus and amygdala of Angelman syndrome model mice by chronic treatment of fluoxetine.

Godavarthi SK, Sharma A, Jana NR.

J Neurochem. 2014 Aug;130(3):444-54. doi: 10.1111/jnc.12726. Epub 2014 Apr 25.

14.

Enhanced Nociception in Angelman Syndrome Model Mice.

McCoy ES, Taylor-Blake B, Aita M, Simon JM, Philpot BD, Zylka MJ.

J Neurosci. 2017 Oct 18;37(42):10230-10239. doi: 10.1523/JNEUROSCI.1018-17.2017. Epub 2017 Sep 20.

15.

Loss of dopaminergic neurons and resulting behavioural deficits in mouse model of Angelman syndrome.

Mulherkar SA, Jana NR.

Neurobiol Dis. 2010 Dec;40(3):586-92. doi: 10.1016/j.nbd.2010.08.002. Epub 2010 Aug 6.

PMID:
20696245
16.

Potential therapeutic approaches for Angelman syndrome.

Bi X, Sun J, Ji AX, Baudry M.

Expert Opin Ther Targets. 2016;20(5):601-13. doi: 10.1517/14728222.2016.1115837. Epub 2015 Nov 26. Review.

17.

UBE3A and Its Link With Autism.

Vatsa N, Jana NR.

Front Mol Neurosci. 2018 Dec 4;11:448. doi: 10.3389/fnmol.2018.00448. eCollection 2018. Review.

18.

Simvastatin Restores HDAC1/2 Activity and Improves Behavioral Deficits in Angelman Syndrome Model Mouse.

Kumar V, Joshi T, Vatsa N, Singh BK, Jana NR.

Front Mol Neurosci. 2019 Nov 26;12:289. doi: 10.3389/fnmol.2019.00289. eCollection 2019.

19.

Toward a Broader View of Ube3a in a Mouse Model of Angelman Syndrome: Expression in Brain, Spinal Cord, Sciatic Nerve and Glial Cells.

Grier MD, Carson RP, Lagrange AH.

PLoS One. 2015 Apr 20;10(4):e0124649. doi: 10.1371/journal.pone.0124649. eCollection 2015.

20.

Tissue-specific variation of Ube3a protein expression in rodents and in a mouse model of Angelman syndrome.

Gustin RM, Bichell TJ, Bubser M, Daily J, Filonova I, Mrelashvili D, Deutch AY, Colbran RJ, Weeber EJ, Haas KF.

Neurobiol Dis. 2010 Sep;39(3):283-91. doi: 10.1016/j.nbd.2010.04.012. Epub 2010 Apr 25.

Supplemental Content

Support Center